Clinical Trial Update: Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Q301 in adolescents and adults with atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Q301

Snippet

Sponsor: Qurient Co., Ltd. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED